Viking Therapeutics Inc
Research Viking Therapeutics Inc (VKTX) on Bullrun: market cap USD 3.99B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVKTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.99B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 128.02M
- Free cash flow-USD 125.17M
Valuation Snapshot
latest market cap is USD 3.99B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 359.64M | -USD 278.69M | n/a | -3.19 | USD 165.81M | USD 137.00K | USD 639.06M |
| FY2024 | USD 0 | -USD 109.96M | -USD 87.79M | n/a | -1.01 | USD 26.68M | USD 1.12M | USD 880.28M |
| FY2023 | USD 0 | -USD 85.90M | n/a | n/a | -0.91 | USD 55.52M | USD 1.26M | USD 348.42M |
| FY2022 | USD 0 | -USD 68.87M | n/a | n/a | -0.9 | USD 36.63M | USD 1.56M | USD 145.32M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.99B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.04B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 4.49B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.86B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 720.87M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 359.94M | n/a | n/a | n/a |
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Viking Therapeutics Inc's market cap?
Viking Therapeutics Inc's market capitalization is USD 3.99B.
What does Viking Therapeutics Inc do?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.